About Us

Neo-Advent Technologies (NAT) is a privately held company headquartered in Marlborough, MA, with its facility in Littleton, MA. It was founded in 2003 by a group of accomplished scientists with diverse backgrounds committed to developing innovative technologies into commercially viable products. Our founders possess decades of combined experience in drug formulation, small molecule synthesis, polymer synthesis, cosmetics, material sciences, and biology. NAT currently provides an extensive set of services to industry, academia and the government.

Our business strategy is to identify areas of specialty needs in the marketplace and match these needs with the latest technology. NAT can take projects from concept through the final product. To learn how we can help you with your technical challenges, please contact us.


“We had tried many drug formulators across the country and overseas, but could not reach target outcomes in our oncology animal models. At that critical time, the NAT team stepped in and played a pivotal role in quickly overhauling the program. Their effort allowed switching from IV to oral means of administration of poorly soluble drug candidates, led to success of decisive toxicology studies, and enabled our IND filings and ongoing early clinical programs in tumor patients.”

Sharon Shacham, Ph.D., CSO, President of R&D, Karyopharm Therapeutics

“NAT’s contribution had a significant impact on our late preclinical program and helped to pave a path to clinical trials. They have addressed many formulation problems in our solid dose form of the lead drug candidate that steered to a vastly improved PK profile and increased its bioavailability.“

Eli Kaplan, M.D., CEO, NovareMed

“VeroScience relies on NAT to assist with its drug formulation and delivery solutions for its lead molecules, and lately, for analytical services, too. The nature of our applications often requires very particular and precise timing for drug release from the finished product. NAT always makes it work, on time and on budget.“

Anthony H. Cincotta, Ph.D., President, VeroScience LLC

Our Team

Nelson Landrau, Co-Founder, President, & CEO

Mr. Nelson Landrau has over 20 years of experience in polymer and synthetic organic chemistry, materials sciences, and drug formulation. He established an excellent track record in the design of advanced coatings and polymeric materials while working for Foster Miller and Eikos, and was credited with multiple patents and two NASA awards for novel thermoset plasticizers for polyimide resins and high temperature micron-sized polymer spheres. At Inotek Pharmaceuticals he spearheaded design and operation of the synthetic scale-up lab and then ventured into the drug formulation arena. Mr. Landrau holds a B.S. degree in Chemistry from the University of Massachusetts.

Alex Nivorozhkin, Ph.D., Co-Founder & Chief Operating Officer

Dr. Nivorozhkin is an entrepreneur and a team builder in the life sciences’ arena with vast experience and a track record in early technology transfer and development. He was a co-founding member of Boston BioCom, LLC, a biopharma company funded by a seed investment from Pfizer. Dr. Nivorozhkin gained substantial experience in the commercial aspects of drug discovery and development at Epix Medical and Inotek Pharmaceuticals, where he served as the Head of Medicinal Chemistry. He served as a Senior Program Manager at the Center for Integration of Medicine and Innovative Technologies (CIMIT) at Massachusetts General Hospital, and also at a consortium of Harvard Medical School-affiliated hospitals, Boston University, Draper Laboratory and MIT aimed at developing new medical devices; and as a Scientific Programs Officer at Sheldon and Miriam Adelson Medical Research Foundation. He is a co-inventor of several drug candidates that have advanced to clinical trials and late pre-clinical studies in the United States, has co-authored over 60 scientific publications in different areas of chemistry, chemical biology, and material sciences, and holds more than 20 patents. Dr. Nivorozhkin received a Ph.D. in Physical Organic Chemistry from Rostov University in Russia and conducted his postdoctoral research at University Paris-Sud, France, and the Department of Chemistry and Chemical Biology, Harvard University.

Pierre Leblanc, Ph.D., Head of Biology

Dr. Leblanc is a biochemist with 20 years of academic and industrial experience in cellular and molecular immunology and biotechnology. His work has focused on studies of regulation and de-regulation of the immune response. He served as Director of Research at Oncogene Products and contributed to the development of novel antibody products and assay designs. He then joined Eikos, Inc. as Director of Molecular Biology and successfully managed several SBIR Phase I & II projects related to US Army-sponsored antimalarial drug development. He has recently carried out research at Shriners Hospital and Massachusetts General Hospital. Dr. Leblanc holds a Ph.D. degree in Biochemistry from McMaster University in Canada. He did postdoctoral research at Boston University and MIT.


Joseph Blanchard, Founder & Managing Director of Biotech Business Advisors LLC

Biotech Business Advisors is a specialty consulting firm that provides clients across the life science spectrum with corporate strategy, business development, fund raising and operations expertise. Mr. Blanchard has over 20 years of leadership experience in the life science industry with companies involved in all facets of the field—drug development, diagnostics, analytical instrumentation, contract research and industrial biotechnology. Previously, Mr. Blanchard was Co-Founder and Chief Business Officer at Aushon BioSystems, Inc., a life science instrumentation company that markets innovative biomarker detection technology for use in drug development and diagnostic applications. He has also held senior management positions with other life science firms, including Genencor International (now owned by DuPont and previously ranked #12 in revenues on the list of biotechnology companies) and Altus Pharmaceuticals (a spin-off of Vertex Pharmaceuticals that had its IPO in 2006). Mr. Blanchard has also served on the board of directors and advisory boards of various drug development, diagnostic and contract research organizations. Joe has B.S. and M.B.A degrees from Miami University.